120 coronavirus vaccines are being developed in the world
US, WASHINGTON (ORDO NEWS) — Currently, there are 120 projects in the world to find an effective vaccine against coronavirus, of which eight are at the stage of clinical trials involving humans. On Tuesday, April 28, the French publication Le Figaro reports with reference to data released by scientists from the London School of Hygiene and Tropical Medicine.
“This well-known British medical school has counted 120 different projects for the development of vaccines against the disease caused by the SARS-CoV-2 coronavirus, including 110 at the” preclinical “stage of development. And eight projects have reached clinical trials of the first phase in humans,” in the message.
Scientists especially note the Chinese project, led by Hong Kong-based CanSino, which is at an even more advanced stage with clinical trials of the first and second phases. It is noted that the main purpose of testing the first phase is to check the safety and, to a lesser extent, the effectiveness of the drug.
The main purpose of the tests of the second phase, and then the third phase, conducted on a larger scale, is to evaluate their effectiveness before granting permission for marketing research by health authorities, experts say.
The London school emphasized that the three leaders are also led by Chinese manufacturers, in particular the pharmaceutical giant Sinovac, which is listed on the Nasdaq American stock exchange, specializing in shares of high-tech companies, and two projects sponsored by the Shenzhen Medical Institute.
The British project of Oxford University and the German BioNTech, which entered the first phase, are also called successful. Two vaccines are also being tested in the United States at this stage. In particular, this medicine is a biotechnological company Moderna in partnership with the American National Institute of Health (NIH) and a drug from Inovio Pharmaceuticals.
—
Online:
Contact us: [email protected]
Our Standards, Terms of Use: Standard Terms And Conditions.
